- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04832477
Assessing the PrEP Care Cascade Among Black Men and Transwomen in the Southeastern US
March 19, 2023 updated by: Lisa Eaton, University of Connecticut
PrEP Connected Study
The proposed research aims to assess the multiple forms and paths of stigma and substance use as they relate to pre-exposure prophylaxis (PrEP) use for HIV prevention.
How stigma and an evolving public health landscape impact PrEP use among Black sexual minorit men who use substances is unknown.
The current application focuses on addressing critical and novel questions to improving the essential building blocks of biomedical prevention approaches by providing crucial information for enhancing interventions to lower HIV prevalence among substance using Black sexual minority men.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
HIV incidence among Black men who have sex with men (BMSM) in the southeastern United States is one of the highest in the world.
Our research team has conducted studies with BMSM in Atlanta that have demonstrated 35% HIV prevalence and over 5% annual HIV incidence.
Although PrEP is highly effective for preventing HIV transmission, it is not reaching BMSM.
The failures in our ability to engage BMSM in PrEP use are highly problematic given the alarming rates of HIV transmission among this group.
Of particular concern is the impact of substance use as a barrier in PrEP linkage, uptake, adherence, and persistence.
Substance use is common among BMSM in our study, with 43% (n=204/474) reporting recent substance use.
Further complicating PrEP use is the potential impact of COVID-19 on health care access, health care infrastructure, and sex behavior.
The need to better understand PrEP use in the context of our new health care landscape is critical to making advances in PrEP use.
At this point, assessing how substance use impacts PrEP use is challenging because PrEP implementation is so low among this group.
The current study aims to provide substance using BMSM with evidence-based PrEP engagement counseling to address barriers to accessing PrEP (not for intervention testing, but for facilitating PrEP use) and to assess the multiple forms and paths of stigma and substance use as they relate to PrEP linkage, uptake, adherence, and persistence.
The investigators propose using the HIV Stigma Framework as a conceptual model for investigating the intersecting pathways of stigma drivers and stigma mechanisms as they relate to PrEP use among substance using BMSM.
Aim 1: Enroll a prospective cohort of N=500 BMSM who test HIV negative and test substance use positive on toxicology testing, and provide evidence-based PrEP engagement counseling to facilitate access to PrEP care.
Aim 2: Conduct psychosocial and health care access assessments every 2-months for 18-months, and conduct HIV/STI testing and dried blood spot testing for TFV-DP every 3-months for 18-months.
Aim 3: Using data collected from Aims 1 and 2, model stigma pathways of advancing and reverting along the PrEP cascade (i.e., linkage, uptake, adherence, persistence), with these pathways mediated by health care access and moderated by substance use.
Achieving the aims will provide critical insight for translating and adapting interventions to enhance potency and durability for individuals at exceedingly elevated risk for HIV.
Study Type
Interventional
Enrollment (Anticipated)
500
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Moira Kalichman, MSW
- Phone Number: 404-892-3500
- Email: moira.kalichman@perceptionsprogram.org
Study Contact Backup
- Name: Lisa Eaton, PhD
- Email: lisa.eaton@uconn.edu
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30303
- Recruiting
- SHARE Project
-
Contact:
- Ayeisha Cole
- Email: ayeisha.cole@perceptionprograms.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Men (based on male sex assignment at birth)
- Age 18 or older
- Identify as Black, African-American, Afro-Brazilian, Afro-Carribean, or African diaspora,
- Report condomless anal sex with man in past six months
- Test HIV negative
- Report recent (<3 months) substance use
- Positive drug toxicology for substance use
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Stigma Counseling for PrEP Access
Behavioral counseling
|
This counseling consists of a single-session (45 minute) delivered by trained peer counselors.
The primary aims and relevant content areas for counseling are: (1) Assessing and discussing factors known to be drivers of emotional barriers to accessing health care.
This counseling aim has two main sub-components: (a) participants will be asked about their prior experiences with accessing health care and their concerns regarding future access, and (b) the counseling will focus on creating personal agency around needing to prioritize one's health.
(2) Evaluating concerns around discussing PrEP with health care providers.
The counseling combines motivational interviewing with medical decisional balance, which focuses on points to consider when evaluating PrEP.
(3) Promoting resiliency beliefs and positive adaptation.
For this objective the counselor works with the participant to establish PrEP use goals and problem-solving strategies.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PrEP Use
Time Frame: 12 months
|
TFV-DP (Tenofovir Diphosphate) biological testing for PrEP pill taking will be assessed.
TFV-DP measured at >700 fmol will be interpreted as having taken ≥4 doses/week, and TFV-DP measured at >700 fmol over two consecutive time points will be interpreted as persistence to taking PrEP.
The lower scale limit is 0 and upper scale limit is approximately around 2500.
Higher values indicate greater medication adherence to PrEP pills.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PrEP stigma
Time Frame: 12 months
|
Questionnaire to assess stigma related psychosocial variables will be used to assess secondary outcomes.
This questionnaire is based measures provided in the HIV Stigma Framework for assessing HIV related stigma (i.e., prejudice, stereotypes, discrimination, enacted stigma, anticipated stigma, and internalized stigma).
Responses to the scale items range from 1=strongly disagree to 6=strongly agree, with higher scores indicating a higher number of experiences of stigma.
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Lisa A Eaton, PhD, University of Connecticut
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 15, 2021
Primary Completion (Anticipated)
February 4, 2026
Study Completion (Anticipated)
February 4, 2026
Study Registration Dates
First Submitted
March 29, 2021
First Submitted That Met QC Criteria
April 1, 2021
First Posted (Actual)
April 5, 2021
Study Record Updates
Last Update Posted (Actual)
March 21, 2023
Last Update Submitted That Met QC Criteria
March 19, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Substance-Related Disorders
- HIV Seropositivity
Other Study ID Numbers
- H20-0117
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Seropositivity
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
-
Therapeutic ConceptsJanssen Scientific Affairs, LLCUnknown
Clinical Trials on Stigma counseling for PrEP use
-
University of Massachusetts, WorcesterEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingPre-Exposure ProphylaxisThailand
-
University of WashingtonNational Institute of Allergy and Infectious Diseases (NIAID); Kenyatta National...Completed
-
University of Massachusetts, WorcesterNational Institute of Mental Health (NIMH); Wayne State University; Institute...RecruitingPre-Exposure ProphylaxisThailand
-
RTI InternationalFogarty International Center of the National Institute of Health; Muhimbili...CompletedDrug Use Stigma in HIV Treatment ClinicsTanzania
-
Wayne State UniversityLoyola University ChicagoCompletedHIV Infections | Substance Use Disorders | Social Stigma | Physician-Patient RelationsUnited States
-
Friends Research Institute, Inc.National Institute on Drug Abuse (NIDA); Johns Hopkins University; University...Enrolling by invitationHIV | Opioid Use | Stigma, Social | Cocaine UseUnited States
-
University of California, Los AngelesUniversity of California, San Diego; California HIV/AIDS Research Program; Los... and other collaboratorsCompletedHIV PreventionUnited States
-
HIV Prevention Trials NetworkNational Institute of Allergy and Infectious Diseases (NIAID); Division of...Enrolling by invitationHIV Infection | Sexually Transmitted Infections | Pre-exposure Prophylaxis | Systems NavigationMalawi
-
East Tennessee State UniversityEnrolling by invitationBehavior | Stigma, SocialUnited States
-
Massachusetts General HospitalMbarara University of Science and TechnologyCompleted